A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 10, 2014

High HCV Cure Rates for BMS Set Stage for Triple Combo Pill

CROI 2014Twelve weeks of Bristol-Myers Squibb’s daclatasvir, asunaprevir and BMS-791325 (’325) cured more than nine out of 10 treatment-naive people with genotype 1 of hepatitis C virus in a recent study, MedPage Today reports. The results open the door for research of a triple-drug combination pill. Results from the randomized, Phase IIb open-label trial were presented at the Conference on Retroviruses and Opportunistic Infections (CROI).

The trial was divided into two groups of participants who received 12 weeks of the NS5A inhibitor daclatasvir, the protease inhibitor asunaprevir and the non-nucleoside ’325. In one group of 80 people, ’325 was dosed at 75 milligrams twice a day, and in another group of 86 people, the drug’s dose was doubled.

Two people discontinued therapy because of adverse side effects. Eleven people experienced virologic failure. The investigators concluded that the only factor that made virologic failure more likely was having genotype 1a of the virus rather than 1b.

Out of the participants for whom the researchers had final data, 92.2 percent (71 out of 77) of those taking the lower dose of ’325 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure) and 91.7 percent (77/84) of those receiving the higher dose achieved an SVR12.

The investigators found that the results of the trial supported the UNITY 1 and UNITY 2 Phase III trials of a twice-daily fixed dose combination pill of all three drugs, with ’325 at the lower dose.

To read the MedPage Today story, click here.

Search: Bristol Myers Squibb, daclatasvir, asunaprevir, BMS-791325, Conference on Retroviruses and Opportunistic Infections, CROI, UNITY 1, UNITY 2, hepatitis C


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dambitious
    Gone
    New York


    InDefaultOf
    Seattle
    Washington


    Sexynyrican
    Brooklyn
    New York


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.